MARKET

CCXI

CCXI

ChemoCentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

59.70
+0.62
+1.05%
After Hours: 59.70 0 0.00% 16:00 07/10 EDT
OPEN
59.08
PREV CLOSE
59.08
HIGH
60.74
LOW
58.27
VOLUME
353.89K
TURNOVER
--
52 WEEK HIGH
65.43
52 WEEK LOW
6.16
MARKET CAP
4.00B
P/E (TTM)
-54.3122
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CCXI stock price target is 74.71 with a high estimate of 95.00 and a low estimate of 65.00.

EPS

CCXI News

More
Insiders Roundup: Mastercard, Eli Lilly
GuruFocus.com · 9h ago
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
GlobeNewswire · 1d ago
ChemoCentryx files U.S. avacopan application for blood vessel inflammation
Seeking Alpha - Article · 1d ago
ChemoCentryx Submits New Drug Application To FDA For Avacopan In ANCA-Associated Vasculitis
Benzinga · 1d ago
3 Perfect 10 Healthcare Stocks That Have Plenty of Growth on Tap
TipRanks · 3d ago
Are Options Traders Betting on a Big Move in ChemoCentryx (CCXI) Stock?
Zacks · 3d ago
ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
GlobeNewswire · 06/24 13:30
ChemoCentryx Reports Identification Of Novel Orally-Administered Immune Checkpoint Inhibitor CCX559 For Next-Gen Cancer Treatment
ChemoCentryx, Inc., (NASDAQ:CCXI) today announced that it has identified an orally administered checkpoint inhibitor, CCX559, and plans to initiate clinical development in the first half of 2021. Data to be presented on
Benzinga · 06/24 12:36

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CCXI

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
More

Webull offers kinds of ChemoCentryx Inc stock information, including NASDAQ:CCXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CCXI stock methods without spending real money on the virtual paper trading platform.